FDA Proposes Faster Gene Therapy Development Path
The U.S. Food and Drug Administration issued draft guidance allowing developers of cell and gene therapies for rare diseases to use prior clinical and manufacturing data to expedite product reviews. This framework aims to streamline submissions by leveraging existing scientific knowledge from similar treatments.
The United States Food and Drug Administration proposed new draft guidance on Tuesday, June 2, to accelerate the development of gene therapies for rare and life-threatening diseases. The framework allows drugmakers to leverage existing scientific data and manufacturing knowledge to bypass certain redundant testing phases.
This shift aims to reduce the high costs and multi-year timelines currently required to bring personalized genetic treatments to market.
